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ABSTRACT:
In the present work, we studied the pharmacokinetics and meta-
bolic disposition of [G-3H]paclitaxel in a female patient with recur-
rent ovarian cancer and severe renal impairment (creatinine clear-
ance: ;20 ml/min) due to chronic hypertension and prior cisplatin
treatment. During six 3-weekly courses of paclitaxel at a dose level
of 157.5 mg/m2 (viz. a 10% dose reduction), the renal function
remained stable. Pharmacokinetic evaluation revealed a reproduc-
ible and surprisingly high paclitaxel area under the plasma con-
centration-time curve of 26.0 6 1.11 mM.h (mean 6 S.D.; n 5 6; c.v.
5 4.29%), and a terminal disposition half-life of ;29 h. Both pa-
rameters are substantially increased (;1.5-fold) when compared
with kinetic data obtained from patients with normal renal function.
The cumulative urinary excretion of the parent drug was consis-
tently low and averaged 1.58 6 0.417% (6 S.D.) of the dose. Total
fecal excretion (measured in one course) was 52.9% of the deliv-
ered radioactivity, and mainly comprised known mono- and dihy-
droxylated metabolites, with unchanged paclitaxel accounting for
only 6.18%. The plasma area under the plasma concentration-time
curve of the paclitaxel vehicle Cremophor EL, which can pro-
foundly alter the kinetics of paclitaxel, was 114.9 6 5.39 ml.h/ml,
and not different from historic data in patients with normal or mild
renal dysfunction. Urinary excretion of Cremophor EL was less
than 0.1% of the total amount administered. These data indicate
that the substantial increase in systemic exposure of the patient to
paclitaxel relates to decreased renal metabolism and/or urinary
elimination of polar radioactive species, most likely lacking an
intact taxane ring fragment.
The antineoplastic agent paclitaxel has been known as a highly
effective chemotherapeutic agent in platinum-refractory ovarian can-
cer since 1989 (McGuire et al., 1989; Ozols, 1998; Wiseman and
Spencer, 1998). Fifteen to thirty percent of patients with cisplatin-
resistant disease respond to paclitaxel treatment, and in up to 7% of
the cases complete remissions can be achieved. These response rates
are even higher in patients with tumors still sensitive to platinum-
containing chemotherapy. Treatment with paclitaxel at a dose of 175
mg/m2 infused over 3 h once every 3 weeks is a widely accepted and
studied regimen in this indication (Ozols, 1998).
The clinical pharmacokinetic behavior of paclitaxel is characterized
by a distinct nonlinear disposition profile (Sonnichsen and Relling,
1994; Gianni et al., 1995), with renal elimination pathways of the
parent drug accounting for less than 15% of the dose (Rowinsky,
1995; Walle et al., 1995). The primary routes of paclitaxel elimination
consist of successive hydroxylation reactions and biliary and intestinal
secretion of the parent drug and its metabolic products (Monsarrat et
al., 1993; Sparreboom et al., 1997). The major metabolic products
identified in humans correspond to two monohydroxylated com-
pounds with a hydroxyl function on the a-position at C6 of the taxane
ring (6a-hydroxypaclitaxel) or on the para-position of the phenyl
group at C39 in the C13 side chain (39-p-hydroxypaclitaxel) and 1
dihydroxylated compound (6a,39-p-dihydroxypaclitaxel) (Harris et
al., 1994a; Sparreboom et al., 1995; Royer et al., 1995). The 6a-
hydroxylation has been shown to be catalyzed by cytochrome P-450
2C8 (Rahman et al., 1994; Cresteil et al., 1994), whereas formation of
39-p-hydroxypaclitaxel appears to be dependent on cytochrome P-450
3A4 (Harris et al., 1994b; Kumar et al., 1994).
Consistent with the importance of hepatic elimination by the cyto-
chrome P-450 family, a recent clinical study with paclitaxel admin-
istered to a large group of patients with liver dysfunction showed a
substantial increase in experienced toxicity (Venook et al., 1998). In
contrast, published pharmacologic data on paclitaxel in adults with
renal failure are very limited and available only in abstract form
(Schilder et al., 1994; Fazeny et al., 1995; Conley et al., 1997). In
addition, it is noteworthy that there are no data of patients with severe,
predialysis renal impairment treated with paclitaxel. In the present
report, we describe the pharmacokinetics of paclitaxel and its formu-
lation vehicle Cremophor EL in a patient with recurrent ovarian
cancer and severely impaired renal function who was treated with six
3-weekly courses of paclitaxel. In one of the courses, we used [G-3H]-
paclitaxel to allow detailed assessment of the elimination routes of
paclitaxel and to determine its complete metabolic fate.
Patient, Materials, and Methods
Patient Characteristics and History. The patient studied was a 65-year-
old Caucasian female, initially diagnosed at 55 years of age with FIGO (i.e.,
the International Federation of Gynaecology and Obstetrics) stage 3C poorly
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differentiated serous ovarian cancer. She was also known to have poorly
regulated hypertension and chronic, slowly progressive renal insufficiency,
presumably due to nephrosclerosis, although a histologic biopsy to prove the
diagnosis was never performed. After successful debulking surgery, the patient
was treated with six cycles of combination chemotherapy consisting of cis-
platin and cyclophosphamide. She remained in complete remission for 7 years,
until December 1996, when there was a local relapse. Second line chemother-
apy with carboplatin and cyclophosphamide again induced a complete remis-
sion; at that time, the creatinine clearance was 30 ml/min. One and a half years
later, the patient again relapsed locally, and was simultaneously diagnosed
with a metastasis adjacent to the transverse colon in the upper abdomen. The
creatinine clearance was decreased to around 20 ml/min, whereas hematopoi-
esis and the results of liver function tests were all normal. It was decided to
treat the patient with a 3-weekly schedule of paclitaxel at the recommended
dose of 175 mg/m2 minus 10% (viz. 157.5 mg/m2) to avoid potential risks
related to the critical preterminal renal insufficiency. During therapy, the
patient did not use any comedication that might have interfered with paclitaxel
disposition. Throughout six courses of treatment, the creatinine clearance
remained stable. The courses were very well tolerated without any sign of
substantial bone marrow suppression or deterioration of other organ functions.
A computer tomographic scan performed after three courses showed a partial
response, which was sustained after an additional three cycles.
Chemicals. Paclitaxel powder (batch 484034; purity 98.3% by reversed
phase HPLC) and commercially available paclitaxel formulated in a mixture of
Cremophor EL and dehydrated ethanol USP (Taxol; 1:1, v/v) were kindly
provided by Bristol-Myers Squibb (Woerden, the Netherlands). The internal
standard for quantitative paclitaxel analysis, docetaxel (batch 14RPOC92320;
purity 98.0% by reversed phase HPLC), was obtained from Rhone-Poulenc
Rorer (Vitry-sur-Seine Cedex, France). Authentic reference standards for 6a-
hydroxypaclitaxel, 39-p-hydroxypaclitaxel, and 6a,39-p-dihydroxypaclitaxel
were obtained after isolation and purification of patient fecal samples, as
described (Sparreboom et al., 1995). Chemical structures of the standards were
confirmed by on-line photodiode array detection and fast atom bombardment
ionization/mass spectrometry, with the compounds dissolved in methanol
added to a glycerol matrix, using a JMS-SX/SX102A Tandem Mass Spec-
trometer (Jeol, Tokyo, Japan) with a 6-keV xenon atom beam and a 10-kV
accelerating voltage. Standards of baccatin III (purity: .95.0%) and 10-
deacetylbaccatin III (purity: .95.0%) from Taxus baccata were purchased
from Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands). [G-3H]Paclitaxel
(batch 227-163-0024; radiochemical purity 99.7%) with a specific activity of
2.4 Ci/mmol was supplied by Moravek Biochemicals, Inc. (Brea, CA). The
majority of the tritium is in the m- and p-positions of the aromatic rings, with
minor amounts in the 10-, 39-, and 2-positions of the taxane ring system (see
Fig. 1). The Cremophor EL reference material was obtained from Sigma
Chemical Co. (St. Louis, MO), and Coomassie brilliant blue G-250 was
purchased from Bio-Rad Laboratories (Munich, Germany) as a concentrated
solution in 85% (w/v) phosphoric acid/95% (v/v) ethanol (2:1, v/v). All other
chemicals and reagents used were of reagent grade or better, and originated
from Rathburn (Walkerburn, UK). HPLC-grade water was obtained from a
Millipore (Milford, MA) Milli-Q-UF system. Ultima Gold scintillation cock-
tail was purchased from Packard (Meriden, CT).
Treatment and Sampling Schedule. The patient studied received the
courses of paclitaxel at a dose level of 175 mg/m2 minus 10% (viz. 157.5
mg/m2) by a 3-h i.v. infusion. In the third course, the dosing solution for
administration was prepared by adding a stock solution of [G-3H]paclitaxel in
absolute ethanol USP to unlabeled paclitaxel in Cremophor EL/ethanol (1:1,
v/v; 6 mg/ml), and diluting this mixture with an aqueous solution composed of
5.25% (w/v) glucose and 0.9% (w/v) sodium chloride. The final dose solution
contained 56.9 ng of [G-3H]paclitaxel per ml, 512 mg of unlabeled paclitaxel
per ml, and 42.7 ml of Cremophor EL per ml (target dose volume, 308 ml/m2).
Blood samples (;5 ml) for pharmacokinetic studies were obtained during all
treatment courses in glass hemogard vacutainer tubes with lyophilized sodium
heparin (Becton Dickinson, Meylan, France) as anticoagulant, and were ob-
tained at the following time points: immediately before dosing; at 0.5, 1, 1.5,
2, 2.5, and 3 h after start of infusion; and at 5, 15, 30, and 45 min and 1, 2, 4,
6, 8, 12, and 24 h after the end of infusion. Samples were centrifuged at 4000g
for 5 min (4°C) to yield the plasma fraction, which was stored frozen at 280°C
in polypropylene vials (Eppendorf, Hamburg, Germany). Complete urine and
feces collections were obtained for up to 5 days, and were stored immediately
at 280°C in polystyrene containers. Aliquots of urine samples were diluted in
10 volumes of drug-free human plasma to prevent continuing degradation of
the analytes (Rangel et al., 1994). Weighted feces samples were homogenized
individually in 10 volumes of water using five 1-min bursts of an Ultra-Turrax
T25 homogenizer (IKA-Labortechnik, Dottingen, Germany) operating at
20,500 rpm. Aliquots of the feces homogenate were diluted with human
plasma before additional sample processing as described above for urine.
Drug Measurement. Paclitaxel concentrations in plasma, urine, and feces
homogenate were measured by reversed phase HPLC with UV detection after
a single solvent extraction, as described (Sparreboom et al., 1998a). Radioac-
tivity in urine and triplicate aliquots of feces homogenate was determined by
liquid scintillation counting using Ultima Gold scintillation cocktail, with a
Wallac System 1400 counter (Turku, Finland). Each sample was pretreated
with a 5-fold volume of acetonitrile by vigorous mixing to remove particulates.
Estimates of residual radioactivity in the particulates were determined after
digestion with 200 ml of sulfuric acid and neutralization of the solubilization
mixture with a 25% (v/v) solution of ammonium hydroxide. All samples were
counted until a preset time of 20 min was reached, with quench correction
performed by external standardization. The analytical procedure for Cremo-
phor EL in plasma was based on a colorimetric binding assay (Sparreboom et
al., 1998b), with modifications as described (Brouwer et al., 1998), using the
Coomassie brilliant blue G-250 dye. Cremophor EL concentrations in urine
were determined using a modification of the same assay, using 1-ml samples
for clean-up and a calibration curve constructed in drug-free urine over a range
of 0.01 to 0.2 ml/ml.
Separation and Identification of Metabolites. Paclitaxel metabolites in
unextracted urine (;1 ml) and fecal extracts (corresponding to approximately
100 mg of feces) were separated and quantified by HPLC with UV detection
or by liquid scintillation counting of collected fractions. The isocratic HPLC
system consisted of a constaMetric 3200 solvent delivery system (LDC Ana-
lytical, Riviera Beach, FL), a Waters 717plus autosampling device (Milford,
MA), a model SpH99 column oven (Spark Holland, Meppel, the Netherlands),
a SpectraPhysics UV-2000 variable wavelength detector (San Jose, CA), and
a FRAC-100 fraction collector equipped with a PSV-50 valve (Pharmacia
Biotech, Uppsala, Sweden). Analytes were separated on a stainless steel
analytical column (150 3 4.6 mm i.d.) packed with a stationary phase of 5 mm
of Inertsil ODS-80A material (GL Science, Tokyo, Japan) supplied with a
Lichrospher 100 PR-18 guard column (4.0 3 4.0 mm; 5-mm particles). The
FIG. 1. Chemical structures of paclitaxel and its known human metabolites.
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mobile phase consisted of water/methanol/tetrahydrofuran/ammonium hydrox-
ide (54.5:45:2.5:0.1, v/v/v/v), with the pH adjusted to 6.0 (formic acid). The
flow rate of the mobile phase was set at 1.0 ml/min with detection performed
simultaneously at 230 and 254 nm, at a column temperature of 60°C. Effluent
fractions (1 ml) were collected, and 3H-labeled metabolites were quantified by
liquid scintillation counting. In each case, the recovery of radioactivity from
the HPLC column was typically .95%. Mass spectra of isolated compounds
were obtained from liquid chromatography/dual mass spectrometry analysis
using a Finnigan MAT LCQ mass spectrometer (ThermoQuest Co., San Jose,
CA) operated with an electrospray ionization probe. Samples were introduced
into the interface through a heated nebulizer probe (500°C) using nitrogen as
nebulizing gas. A discharge voltage of 3.3 kV was applied to the corona
discharge needle to produce a discharge current of 5 mA, with a capillary
temperature adjusted to 175°C. The tube lens offset voltage was adjusted to
140 V to maximize sensitivity by balancing desolvation with fragmentation.
mass spectrometry data were collected over m/z 200 to 1000.
Pharmacokinetic Data Analysis. Plasma concentration versus time data
were analyzed using the Siphar software package (version 4.0; SIMED, Cre´-
teil, France), by determination of slopes and intercepts of the plotted curves
with multiexponential functions. The program determined initial parameter
estimates, and these were improved using an iterative numerical algorithm
based on Powell’s method. Model discrimination was assessed by a variety of
considerations including visual inspection of the predicted curves, dispersion
of residuals, minimization of the sum of weighted squares residuals, and the
Akaike and Schwartz information criteria. Final values of the iterated param-
eters of the best-fit equation were used to calculate pharmacokinetic parame-
ters, including drug disposition half-lives (T1/2), area under the plasma con-
centration-time curve (AUC)1 from zero to infinity, total plasma clearance, and
steady-state volume of distribution, using standard equations. The peak plasma
concentration (Cmax) was put on par with the observed drug level at the end of
infusion. Statistical evaluation and noncompartmental analysis of Cremophor
EL plasma concentration data was performed as described previously (Spar-
reboom et al., 1998c).
Results
Analytical Methods. To gain a preliminary insight into the com-
position of the paclitaxel metabolites present in the various biological
matrices, samples from the patient were initially analyzed by our
HPLC procedure developed for plasma (Sparreboom et al., 1998a).
This method was subsequently modified for analysis in feces homog-
enates and urine, so that baseline resolution of all the chromatographic
peaks observed in samples could be achieved. Using this HPLC
system, mean chromatographic run times for known compounds were
established using pure reference substances at 3.61 min (10-deacetyl-
baccatin III), 5.50 min (baccatin III), 15.0 min (6a,39-p-dihydroxypa-
clitaxel), 18.8 min (39-p-hydroxypaclitaxel), 35.0 min (6a-hydroxypa-
clitaxel), and 51.8 min (paclitaxel). Structural identification of
unknown compounds was based on HPLC data, UV absorption char-
acteristics at 230 nm, and mass spectrometry of isolated peaks relative
to reference derivatives.
Plasma Disposition. The plasma concentration-time profiles of
unchanged paclitaxel were remarkably similar for the six consecutive
treatment cycles studied. All the profiles were best fitted to a three-
compartmental model after zero-order input using the Powell mini-
mization algorithm and weighted least-squares analysis with a weight-
ing factor of 1/Y. The mean plasma pharmacokinetic parameters of
paclitaxel, as calculated by this triexponential model are listed in
Table 1. Plasma concentrations of paclitaxel decreased rapidly imme-
diately after cessation of the 3-h infusion (Fig.2A), followed by a
more prolonged disposition half-life of ;29 h, which is approximately
1.5-fold higher as compared with data reported previously in patients
with normal renal function (Gianni et al., 1995). Similarly, the pac-
litaxel plasma AUC extrapolated to infinity was very reproducible and
achieved surprisingly high values of 26.0 6 1.11 mM/h (mean 6
S.D.).
Urinary and Fecal Disposition. The urinary excretion pattern,
measured on three consecutive courses, was virtually identical
throughout these treatment courses, with 1.58 6 0.417% of the dose
excreted as unchanged drug in the first 24 h after drug administration
(Table 2). The mean renal clearance of paclitaxel, defined as the
product of the dose-fraction excreted unchanged and total body clear-
ance, was 0.181 6 0.047 liter/h, indicating that as much as 98% of the
overall clearance could be attributed to nonrenal processes. The total
cumulative urinary excretion of radiolabeled compounds after
[G-3H]paclitaxel administration accounted only for 2.25% of the dose,
of which 1.15% constituted metabolic products. Reversed phase
HPLC tracings with UV detection and scintillation detection of a urine
extract from a urine sample collected during the first 3 h after dosing
are presented in Fig. 3. In addition to the parent drug, trace levels of
10-deacetylbaccatin (MH1 ion at m/z 545) and baccatin III (MH1 ion
at m/z 587) could be detected (both accounting for less than 0.01% of
the dose), and an unknown prominent radioactive peak early in the
solvent front that was reported previously (Walle et al., 1995; Spar-
reboom et al., 1997).
Data of fecal elimination, obtained only during the third treatment
course, indicated that 52.9% of the delivered radioactivity was ex-
creted in the first 24 h, with unchanged paclitaxel accounting for only
6.18%. In fecal extracts, 6a-hydroxypaclitaxel (MH1 ion at m/z 870;
taxane fragment ion at m/z 525) could clearly be distinguished as the
predominant species (see Fig. 2A). Using reference derivatives, two of
the additional paclitaxel metabolites could be identified as 6a,39-p-
dihydroxypaclitaxel (MH1 ion at m/z 886) and 39-p-hydroxypacli-
taxel (MH1 ion at m/z 870; taxane fragment ion at m/z 509). The peak
labeled 1 in Fig. 2A showed a molecular ion at m/z 870 and a fragment
ion at m/z 509, suggesting an unknown metabolite(s) resulting from a
single hydroxylation reaction in the C13 side chain. A second uniden-
tified peak (labeled 4 in Fig. 2A) had an abundant ion at m/z 286
(unmodified C13 side chain) and other characteristic fragments at m/z
509, 525, 792, and 810. This metabolite is most likely either
4-deacetylpaclitaxel or 10-deacetylpaclitaxel, resulting from a loss of
the acetyl moiety on C4 or C10, respectively, of the taxane nucleus
(Anderson et al., 1995; Monsarrat et al., 1998).
Cremophor EL Kinetics. Disappearance of the paclitaxel formu-
lation vehicle Cremophor EL from the plasma compartment was
characterized by elimination in an apparent biexponential manner
(Fig. 2B). The peak plasma concentrations and AUC values of Cre-
mophor EL in the three subsequent cycles, shown in Table 1, were
3.51 6 0.17 ml/ml (mean 6 S.D.) and 114.9 6 5.39 ml.h/ml, respec-
1 Abbreviations used are: AUC, area under the plasma concentration-time
curve.
TABLE 1
Plasma pharmacokinetic parameters of paclitaxela
Compound AUC0-t AUC0-` Cmax T1/2(z) Vd,ss Cl
mM.hb mM.hb mMc h liters liters/h
Paclitaxel
Mean 20.30 26.18 5.810 23.7 401 11.2
S.D. 1.26 1.25 0.745 5.21 54.5 0.55
c.v. 6.21 4.77 12.8 22.0 13.6 4.91
Cremophor EL
Mean 56.89 114.9 3.51 27.1 7.07 0.186
S.D. 1.283 5.393 0.170 2.97 0.46 0.009
c.v. 2.25 4.69 4.89 11.0 6.49 4.58
a Abbreviations: Cmax, peak plasma concentration; T1/2(z), half-life of terminal disposition
phase; Vd,ss, steady-state volume of distribution; Cl, total plasma clearance; c.v., coefficient of
variation.
b ml.h/ml for Cremophor EL.
c ml/ml for Cremophor EL.
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tively, and are consistent with earlier findings obtained from a large
cohort of patients treated with paclitaxel at a similar dose of 150
mg/m2 (Sparreboom et al., 1998c). The cumulative urinary excretion
of Cremophor EL was very low and accounted for 0.08 6 0.02%
(mean 6 S.D.) of the administered dose.
Discussion
The administration of paclitaxel to patients with renal insufficiency
has been reported previously in five cases and in all, patients were on
(long-term) hemodialysis (Schilder et al., 1994; Fazeny et al., 1995;
Balat et al., 1996; Conley et al., 1997; Woo et al., 1999). Although
paclitaxel pharmacokinetics was determined in some of these patients,
the lack of fecal and urinary data precluded a complete analysis of
paclitaxel disposition. In contrast to these previous investigations, we
evaluated paclitaxel plasma pharmacokinetics during six sequential
evaluated courses. Our patient exhibited a quantitatively distinct ki-
netic profile of paclitaxel, with paclitaxel AUC values and disposition
half-lives in plasma approximately 1.5- to 2-fold higher as compared
with those reported in patients with normal renal function (Rowinsky,
1995; Gianni et al., 1995). This high paclitaxel AUC value, which was
sustained over the six consecutive courses, justifies a dose reduction
of paclitaxel in patients with severe predialysis renal impairment
although, surprisingly, no major (hematological) toxicity, other than
mild fatigue, was observed in this patient.
We have recently shown that Cremophor EL, the formulation
vehicle used for i.v. paclitaxel administration, causes a profound
concentration-dependent alteration of drug accumulation in erythro-
cytes by reducing the free drug fraction available for cellular parti-
tioning (Sparreboom et al., 1999). This phenomenon is caused by
micellar incorporation of paclitaxel in the systemic circulation and
results in increased plasma concentrations and ‘artificial’ nonlinear
disposition (Sparreboom et al., 1996). Because no data were available
on Cremophor EL kinetics in patients with renal failure, we speculated
that the increased exposure of our patient to paclitaxel, expressed as
the AUC in plasma, might have been caused by alteration of Cremo-
phor EL disposition and elimination. However, involvement of Cre-
mophor EL in the observed kinetic behavior of paclitaxel could
eventually be ruled out as the plasma clearance and AUC were
comparable with those reported previously in a historic control group
of patients with normal renal function on a similar treatment schedule
(Sparreboom et al., 1998c). Consistent with this observation, we
found that urinary excretion of Cremophor EL, despite its relatively
hydrophilic nature, accounted for only less than 0.1% of the delivered
dose in this patient. This suggests that renal excretion of intact
Cremophor EL and its major constituent polyoxyethyleneglycerol
triricinoleate is not important in the overall elimination of this vehicle
substance.
Alternatively, we investigated the possibility that metabolic routes
and excretion pathways of paclitaxel itself might have been altered
due to the disease state of the patient. This was achieved by the use of
radiolabeled paclitaxel in the third treatment course. As demonstrated
previously, fecal excretion constituted the main route of excretion,
with 52.9% of the administered radioactivity recovered in a 24-h feces
FIG. 2. Plasma concentration-time curves of paclitaxel (A) and of Cremophor EL (B).
Pharmacokinetic data were obtained from a female patient receiving six 3-weekly courses of the drug formulated at 6 mg/ml in a mixture of Cremophor EL-dehydrated
ethanol USP (1:1, v/v) at a dose level of 157.5 mg/m2. Data are presented as mean values (symbols) 6 S.D. (error bars).
TABLE 2
Elimination kinetics of paclitaxel, total radioactivity, and metabolitesa
Parameter Course I Course II Course III
Paclitaxel
ClT (liters/h) 10.9 10.8 11.8
ClR (liters/h) 0.201 0.214 0.127
ClNR (liters/h) 10.7 10.6 11.7
feurine (%) 1.85 1.79 1.10
fefeces (%) n.d. n.d. 6.18
Radioactivity
feurine (%) n.d. n.d. 2.25
fefeces (%) n.d. n.d. 52.9
Total metabolites
feurine (%) n.d. n.d. 1.15
fefeces (%) n.d. n.d. 46.8
a Abbreviations: ClT, total body clearance; ClR, renal clearance; ClNR, nonrenal clearance; fe,
percentage of the absolute paclitaxel dose excreted in urine or feces as unchanged drug, total
radioactivity, or total paclitaxel metabolites; n.d., not done.
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collection period. This is in excellent agreement with earlier data of
Walle et al. (1995), who reported that 59.1 6 7.3% of the total dose
was excreted as extractable radioactivity in five patients with normal
organ functions. In line with this study and with our own work
characterizing the main hepatic metabolites in patient feces samples
(Sparreboom et al., 1995), only approximately 6% of the fecal radio-
activity was excreted as unchanged paclitaxel. 6a-Hydroxypaclitaxel
constituted the major metabolite, with 39-p-hydroxypaclitaxel and
6a,39-p-dihydroxypaclitaxel both present as minor biotransformation
products, in addition to two unknown compounds. In contrast to fecal
data, the cumulative urinary excretion of radiolabeled paclitaxel was
significantly different from other published data (Walle et al., 1995);
the total urinary excretion of 3H-labeled paclitaxel and metabolites
accounted for 14.3 6 1.4% (range, 11.0–18.7%) of the dose, with the
parent drug representing 4.5 6 0.5% (range, 3.3–6.2%) versus 2.25%
(total radioactivity) and 1.58 6 0.42% (paclitaxel), respectively, in
our patient. These comparative data seem to indicate that renal elim-
ination of paclitaxel and its metabolites, particularly the large un-
known polar constituents, which may represent (part of) the C13 side
chain, is markedly impaired, and this may have contributed to the
altered pharmacokinetic profile observed in plasma.
In conclusion, we have shown altered plasma pharmacokinetics of
paclitaxel in a patient with severely impaired renal function, treated at
a 10%-reduced dose during six consecutive courses. Our findings
indicate that the substantial increase in systemic exposure of our
patient to paclitaxel most likely relates to decreased renal metabolism
and/or urinary excretion of unchanged drug or polar radioactive
species. These data point to a more prominent role of the kidneys in
paclitaxel disposition than previously thought and suggest that addi-
tional studies are required to fully appreciate to what extent renal
dysfunction can affect paclitaxel pharmacokinetics and pharmacody-
namics. Such studies should focus on mechanisms by which any
difference observed might be explained.
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